- Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Clalit Health Services
Not yet recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: RoActemra/Actemra (tocilizumab)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Drug: Erlotinib; Drug: Bevacizumab
Sponsors: European Thoracic Oncology Platform; European Thoracic Oncology Platform; Spanish Lung Cancer Group
Not yet recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Gastric Adenocarcinoma
Intervention: Drug: Capecitabine, Oxaliplatin, Docetaxel
Sponsors: National Health Research Institutes, Taiwan; National Health Research Institutes, Taiwan; Taipei Veterans General Hospital,Taiwan; Tri-Service General Hospital; Mackay Memorial Hospital; National Cheng-Kung University Hospital
Active, not recruiting - verified March 2012 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified February 2012 - Condition: Osteoarthritis, Knee
Intervention:
Sponsors: Orthosensor, Inc.; Orthosensor, Inc.
Recruiting - verified January 2012 - Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Interventions: Drug: everolimus; Drug: GDC-0980
Sponsors: Genentech; Genentech
Not yet recruiting - verified September 2011 - Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: diazepam; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rectal Cancer
Intervention: Drug: capecitabine, oxaliplatin, bevacizumab
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: HER-2 Positive Breast Cancer
Intervention:
Sponsors: Asociación para el Progreso de la Oncología en Málaga; Asociación para el Progreso de la Oncología en Málaga; Roche Farma, S.A.
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified August 2011 - Conditions: Sustained Virologic Response; IL28B Polymorphism
Interventions: Drug: peginterferon alfa 2a (pegasys); Drug: peginterferon alfa-2a (pegasys)
Sponsors: The Catholic University of Korea; The Catholic University of Korea; Ulsan University Hospital; NHIC Ilsan hospital; Inje University; Soonchunhyang University Hospital; Yonsei University; Chungnam National University; Keimyung University; Kyungpook National University; Konyang University Hospital; Inha University Hospital; Hallym University Medical Center
Recruiting - verified October 2008 - Condition: Solid Cancers
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Spanish Breast Cancer Research Group; Spanish Breast Cancer Research Group; Roche Farma, S.A.
Completed - verified June 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel; Drug: Trastuzumab, Docetaxel, Bevacizumab; Drug: Trastuzumab+Docetaxel+NPLD; Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Hoffmann-La Roche; Cephalon
Recruiting - verified April 2012 - Conditions: Cytomegalovirus Infection; Hepatitis C
Intervention:
Sponsors: Sociedad Española de Trasplante Hepático; Sociedad Española de Trasplante Hepático; Roche Farma, S.A.
Recruiting - verified November 2011 - Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid TumorsCondition: Solid Tumour
Intervention: Drug: MFGR1877S
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Solid Cancers
Interventions: Drug: docetaxel; Drug: GDC-0068; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
 |
Roche Global - Database of Clinical Trials by Pharmaceutical Companies |
